Mineralys Therapeutics, Inc. (MLYS)
After hours:
| Previous close | 13.15 |
| Open | 13.12 |
| Bid | 12.94 x 100 |
| Ask | 13.04 x 100 |
| Day's range | 12.83 - 13.18 |
| 52-week range | 5.85 - 17.44 |
| Volume | |
| Avg. volume | 145,133 |
| Market cap | 645.431M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.18 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.50 |
Insider MonkeyMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript May 11, 2024 Mineralys Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Mineralys First Quarter 2024 Earnings Conference Call. At […]
Simply Wall St.We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
GlobeNewswireMineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 – – Ongoing Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is anticipated to deliver topline data in Q4 2024 to Q1 2025 – – Conference call today at 8:30 a.m. ET – RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a
